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AbstrAct
WHO recognises the global impact of sexually 
transmitted infections (STIs) on global public health 
and individual sexual and reproductive health and 
well-being. As a component of the WHO Global Health 
Sector Strategy for the control and prevention of STIs, 
there has been a growing recognition of the importance 
of integrating point-of-care tests (POCTs) into overall 
strategic planning. The process of integrating STI POCTs, 
in addition to providing a definitive diagnosis and 
appropriate treatment in a single visit, also includes 
innovative delivery options, such as on-site delivery, 
community-based testing (including screening), as well 
as self-testing at home after purchase of a test online 
or over-the-counter. WHO organised two technical 
consultations in May 2014 and July 2015. This article 
summarises the discussions of the meeting participants 
on advancing the use of POCTs to control and prevent 
STIs. The following priorities were identified: the need 
for pathogens’ target discovery; encouragement 
of multiplexing, miniaturisation, simplification and 
connectivity; promotion of standardisation of evaluation 
of new diagnostic platforms across all stages of the 
evaluation pipeline; the need for an investment case, 
modelling and scenarios to ensure buy-in among key 
stakeholders, including developers and the private sector; 
the need for norms and standards, including guidelines, 
to support introduction of STI POCTs in programmes; 
anticipating potential tensions between different parties 
at the implementation level; and leveraging on the global 
initiative, Sustainable Development Goals (SDGs)/global 
health sector STI strategy, to sustain investment in STI 
POCT programmes. There is a rich pipeline of diagnostic 
products, but some have stalled in development. An 
approach to accelerate the evaluation of new diagnostics 
is to set up a competent network of evaluation 
sites ahead of time, harmonise regulatory approval 
processes with development of models to estimate cost-
effectiveness, informed by better STI data. This should 
result in accelerating policy development. Although it 
may be some time before good POCTs can be widely 
implemented in low resource settings, it is important 
to be a catalyst for continued development and use of 
these essential tools as an integral part of both the WHO 
Global Health Sector Strategy and the agenda for 2030. 
IntroductIon
WHO recognises the global impact of STIs on global 
public health and individual sexual and reproduc-
tive health and well-being. As a component of the 
WHO Global Strategy for the Control and Preven-
tion of STIs, there has been a growing recognition 
of the importance of integrating point-of-care 
tests (POCTs) into overall strategic planning.1 
Advancement of these technologies would allow 
the delivery of aetiology-based diagnosis to move 
from centralised laboratory-based testing to a clin-
ic-based approach closer to the setting in which 
patients seek healthcare. This approach could serve 
many of the goals in the global strategy and provide 
patients and clinicians with a rapid diagnosis and a 
better informed basis for treatment.
The STI POCT concept, in addition to enabling a 
definitive diagnosis and appropriate treatment in a 
single visit, also includes innovative delivery options, 
such as on-site delivery, community-based testing 
(including screening), as well as self-testing at home 
after purchase of a test online or over-the-counter.2
In support of this concept, WHO organised 
two technical consultations, one in May 2014 
and the other in July 2015. These consultations 
brought together international experts from all 
WHO regions to review the progress of POCTs 
and to identify challenges and gaps that need to be 
addressed to advance their development and use for 
the control and prevention of STIs.
During the first consultation, the international 
expert group (IEG) on STI POCTs was established. 
These experts reviewed the results of the land-
scape analysis of promising STI diagnostic tech-
nologies and tests, and of systematic reviews on 
the performance and operational characteristics of 
STI POCTs. The IEG also defined target product 
profiles (TPPs) for the development of new STI 
POCTs and advised on further research.
The objectives of the second consultation were to 
finalise core protocols for independent evaluation 
of promising STI POCTs, to consider the imple-
mentation of the core protocols in selected coun-
tries and to develop a roadmap for the development 
of new STI POCTs, including the research needs for 
new product development.
Meeting participants focused on the development 
of tests for which aetiological diagnosis potentially 
has the greatest impact: dual HIV/syphilis tests, 
tests for the detection of Neisseria gonorrhoeae 
(gonorrhoea), Chlamydia trachomatis (chlamydia) 
and Trichomonas vaginalis (trichomoniasis), at both 
urogenital and extragenital sites, as well as tests for 
human papillomavirus infection. The current article 
summarises the discussions among the meeting 
participants to advance the use of POCTs to control 
and prevent STIs.
GAps, needs And prIorItIes
Inspired by the global roadmap for STI vaccine 
development,3 discussions were structured along 
four main development phases necessary for 
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advancing products from the laboratory to routine use (figure 1): 
basic research, translation, evaluation and programmatic imple-
mentation. For each phase, meeting participants identified crit-
ical gaps in knowledge, current and future needs and formulated 
important priorities for accelerating development and global 
uptake of POCTs in public health strategies. To sustain develop-
ment of all diagnostic tools related to STIs, all participants reit-
erated the urgent need for better epidemiological data (estimates 
and surveillance) and for improving the understanding of STI 
natural history and burden of sequelae, similar to views expressed 
for the STI vaccine development.4 These advances, which will 
not be discussed in detail here, are needed to break the cycle of a 
lack of appropriate and affordable STI diagnostic tools resulting 
in a lack of STI surveillance data. This gap in knowledge, in turn, 
may limit the interest in STI diagnostics development. Higher 
quality data on both STI trends and burden are one of the main 
drivers to advance STI diagnostic development.
Before the participants discussed the way forward for POCTs, 
it was acknowledged that a range of definitions currently exists 
for the term, POCTs. In the absence of a universally accepted 
definition the WHO STI Diagnostics Initiative developed the 
ASSURED criteria as a benchmark to decide if tests address 
disease control needs: Affordable, Sensitive, Specific, User-
friendly, Rapid and Robust, Equipment-free and Deliverable 
to end-users.5  These criteria have guided many POCT eval-
uations and development of new POCTs but have also been 
criticised for being too subjective and lacking quality assur-
ance on the one hand and on the other for creating artificial 
restrictions on the concept of POCT, possibly discouraging 
developers from pursuing their endeavours.6 Equipment-free 
has over the years moved to minimal equipment, meaning 
portable, simple, mobile devices requiring minimal infrastruc-
tural support and affordability has been complemented with 
cost-effectiveness.
The POCT concept is not only determined by technology 
but should also be determined by context and the end-users, 
both providers and patients. Most experts share the vision that 
STI POCTs should encompass, as a minimum: testing performed 
on-site during the patient consultation to permit a rapid test 
result to be generated and used to make an immediate, informed 
clinical decision.7 However, some meeting participants ques-
tioned what on-site means, when with the current technologies, 
home-based testing could be complemented with online counsel-
ling and prescription. However, these technologies are currently 
not available in low-income and middle-income countries, which 
bear 80%–90% of the global STI burden.8
Notwithstanding the lack of a universal definition, the IEG 
decided on TPPs for five STIs, described earlier in this supple-
ment, which are available on the website of WHO to guide 
researchers, manufacturers as well as policy makers.9
bAsIc reseArch
Gaps
Meeting participants agreed that while current products hold great 
potential, to maintain a robust development pipeline, basic research 
is essential to generate new potential avenues and approaches.
Figure 1 Development cycle of STI POCTs.
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There are gaps in antigen discovery and diagnostic target iden-
tification for STIs. For syphilis, markers (specific host or path-
ogen proteins and  antigens or other biomarkers) are lacking to 
easily and rapidly distinguish acute infection from prior infec-
tions, both in adults and infants. For gonorrhoea, there is a need 
to address antimicrobial resistance (AMR) by developing new 
rapid methods to determine susceptibility to relevant antibiotics 
without resorting to culture.10 This has the potential to provide 
patient-specific information in a time frame that allows clinicians 
to prescribe individualised treatment regimens.11 For chlamydia, 
the meeting participants observed poor sensitivity of immuno-
chromatographic tests to detect chlamydial antigens, especially 
if these rapid tests are to be used for screening asymptomatic 
patients with low bacterial loads.
the way forward
Encourage target discovery
Participants suggested the development of a TPP for POCTs 
specifically for the elimination of mother-to-child transmis-
sion of syphilis. There is a need for a novel marker of active 
syphilis that can be detected using easy, low-tech, low-cost and 
effective technologies to replace the detection of non-trepo-
nemal antibody (reagin) as a proxy of active syphilis, given the 
dilemma whether to repeat treatment for patients with persistent 
non-treponemal antibody. Identifying new markers for active 
syphilis is a high-risk undertaking, it should however not be 
neglected by developers, as it is a critical tool for the elimination 
of mother-to-child transmission of syphilis and management 
of the ‘serofast’ patient. Both the utility of absolute titres and 
comparison of titres over time, and between the baby versus the 
mother, should be considered.
Participants recommended the identification of genetic markers 
to predict gonococcal resistance/susceptibility, including nucleic 
acid targets, against recommended therapeutic agents for gonor-
rhoea. The frequency of potential diagnostic targets in different 
gonococcal genotypes and populations should be investigated. 
Current technologies are complicated, requiring multiple steps, 
trained personnel and may take more than 48 hours to perform. 
The novel resistance markers should be incorporated into a 
POCT to track resistance.
Encourage integration and miniaturisation of sample preparation 
and target detection
As was pointed out in the landscape of POCTs in this supple-
ment, sample preparation and target detection are two key 
processes in diagnostics. ‘Next-generation’ technologies, such 
as microfluidics and nanotechnology, enabling the integration 
and miniaturisation of both processes, should be fully supported 
to overcome these barriers.12 Although miniaturisation allows 
complex technologies to be used at POC, it should be noted that 
the smaller sample size required for these nanoscale reactions 
poses a risk that test sensitivity would be poor unless the diag-
nostic target is present in ample amounts.13
The AMR opinion paper in this supplement shows that micro-
fluidic and nanotechnology platforms provide a basis to develop 
molecular POC–AMR diagnostics. However, particularly for 
gonorrhoea, more knowledge is required to assess which antibi-
otic classes lend themselves to a genotypic POC–AMR approach. 
It is difficult to estimate the potential clinical and epidemiological 
impact of using a genotypic approach when genotypic–pheno-
typic relationships for N. gonorrhoeae are not well understood.14
It could be beneficial to improve and promote non-invasive 
sample collection where possible, for example, urine among 
men and women in the case of urethrogenital infections, and 
saliva in case of systemic infections like syphilis, without jeop-
ardising the analytical performance of STI POCTs. Diagnostic 
platforms should be calibrated according to the quantity of path-
ogen targets in samples in order to ensure acceptable levels of 
sensitivity and specificity.
Promote international and multisectorial research cooperation
To enable research in low-resource settings, participants 
suggested the creation of biobanks to gather available well-char-
acterised specimens that can be accessed by various stakeholders.
The knowledge of conserved diagnostic target sequences 
across the globe could be improved by expanding genomic 
sequence databases.
Although the field of STI POCTs is advancing, initiatives 
to prompt the uptake of novel technologies have been scarce 
compared to the POCT field in other areas in clinical medicine.15 A 
literature review should be conducted to identify promising cross-
over initiatives, both for STIs and emerging infectious diseases.
trAnslAtIon
Gaps
The two main gaps in the translation of basic research to proto-
type products are interrelated. While there is a lack of multi-
plex platforms that combine the detection of several STIs into 
a single POCT, and potentially other infectious diseases, many 
of the current and future technologies will not be accessible or 
affordable for patients in the developing world.
The participants felt that not all potentially viable basic research 
is translated to products by diagnostic companies, and when it 
is translated, there is often a disconnect between the aims of the 
companies and the preferences of the end-users, both patients 
and providers. These are very much linked and should be directly 
informed by the stage of implementation and programming.
The IEG also pointed to the underuse of the enormous poten-
tial that connectivity technology currently offers.16
the way forward
Prioritise the development of miniaturised multiplexable STI POCT 
platforms
The development of a POCT that simultaneously screens for 
multiple pathogens from a single specimen should be prioritised 
because the same clinical symptoms can be caused by infections 
by many aetiological agents and mixed infections are common.12 
Moreover, disease and therapeutic response often involve inter-
play between many biological processes.13 Multiplexing could 
also potentially increase throughput and data generation while 
simplifying formats and decreasing the time and cost required 
to operate tests, which makes them more fit for use in low- and 
middle-income settings than current POCT platforms.
The IEG stressed the need for further developing next-gen-
eration platforms and prototypes to miniaturise the products, 
their footprints and turnaround time and combining them to 
achieve multiplexing optimisation. Target combinations should 
be optimised to improve global strain coverage while reducing 
any signal interference. The possibility of having a multiplex 
pregnancy/HIV/syphilis POCT was raised.
One of the very promising prototypes uses microfluidics and 
lab-on-chip technology, capable of detecting major causes of STIs 
simultaneously at very low cost per test.17 It is, however, not yet 
commercially available nor widely evaluated. Another prom-
ising approach, which combines both spatial and spectral multi-
plexing, uses quantum dots, potentially increasing the multiplexing 
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capabilities of immunoassays.13 Recent developments in paper-
based microfluidic assays together with novel assay formats have 
also unprecedentedly expanded the number and complexity of 
tests that can be conducted using low-cost and disposable POCT 
kits, particularly in the developing world.18 A more comprehensive 
overview of the next-generation technologies can be found in the 
landscape article in this supplement.
Include researchers, manufacturers and end-users in the 
translational phase of POCTs
The meeting participants acknowledged that in most settings, few 
appropriate tests are available. Part of the reason being that the 
scientists and engineers who design these tests, and the compa-
nies who develop and market them, are usually based in affluent 
countries and are often unaware of settings and the real needs of 
the end-users in the developing world.19 Bringing them together 
with end-users, providers and patients, in the translational stage 
of POCT development creates an opportunity for proactive prob-
lem-solving, discussions about trade-offs and device design.20 21 
In addition, used to working with few resources and local health-
care professionals might come up with simple yet innovative solu-
tions to challenges around cost-effectiveness.
The IEG stressed the need for more qualitative studies in different 
settings and populations, to assess end-users’ requirements.22
Capitalise on the advances in connectivity for STI-surveillance, 
testing uptake and quality control of STI POCTs
If an STI POCT comes with a reader and is introduced in a whole 
region or country, connectivity may be used for STI surveillance 
purpose.23
Quality control is not often included in the translation stage 
of POCT development. Reader devices should be an asset for 
enhancing quality control programmes. If data are not coming 
in, programme managers can immediately investigate the reason 
(personnel, supplies, treatment stock-outs, etc) and initiate 
corrective action. Connectivity solutions can be leveraged to 
turn system stresses into increasing efficiency.
The meeting participants agreed on the need of AMR—
research in N. gonorrhoeae to capitalise on the fact that mobile 
phones are widespread globally, even in low- and middle-in-
come settings, although not all. Mobile phones and smartphone 
applications could facilitate reading POCT test results, promote 
uptake and increase follow-up. STI apps might lead to more 
testing.24 The fact that current STI apps have a marked variation 
in content, quality and accuracy, some even contain potentially 
harmful information,25 calls for the need to invest in a free, good 
quality e-health approach to sexual health and well-being, which 
could complement and reinforce the introduction of STI POCTs.
The IEG also emphasised the need of making TTPs for self-ad-
ministered, home-based STI diagnostic tools, which can be 
purchased online or through apps.26
evAluAtIon
Gaps
The IEG recognised the lack of independent evaluations of 
currently available POCTs, both laboratory-based and clin-
ic-based, and utility evaluations. In particular, the test perfor-
mance on pharyngeal and rectal swabs for gonorrhoea, 
chlamydia and trichomoniasis is lacking, since most companies 
do not have an indication for their tests to be used on these 
specimens. Little is also known about the cost-effectiveness of 
pooling specimens for low-prevalence settings. There is also a 
lack of clinic-based and utility evaluations in key populations, 
for which STI POCTs seem to be particularly appropriate, and in 
low- and middle-income settings. In addition, as the reviews in 
this supplement indicate, the quality of evaluations undertaken 
in the past has been very uneven. For example, reference testing 
is often problematic.27
the way forward
Promote standardised high-quality laboratory, clinic-based and 
utility evaluations of STI POCTs
The IEG welcomed the initiative of WHO to prepare core proto-
cols for laboratory, clinic-based and utility evaluation of STI 
POCTs and indicated those STIs for which POCTs are most urgent 
and the populations in greatest need of them. The research prior-
ities for diagnostic tests in a public health setting are based on the 
main challenging areas in terms of STI control from a diagnostic 
perspective. Linking the discussion on STI POCTs to STI case 
management as well as STI control and prevention in key popula-
tions, the following priorities were identified:
 ► Chlamydia/trichomoniasis: high prevalence, understanding 
the purpose of regular screening in women at risk;
 ► Gonorrhoea: increase of resistance in N. gonorrhoeae, 
increasing the need for scaling up regular screening of 
women at high risk;
 ► Chlamydia/gonorrhoea/trichomoniasis: case management 
vaginal discharge syndrome needs to optimise case manage-
ment through introduction of testing;
 ► Chlamydia/gonorrhoea: screening in men who have sex with 
men (MSM) in extragenital anatomic sites: using pharyngeal 
and anorectic swabs;
 ► Dual HIV/syphilis: screening in antenatal care (ANC) as well 
as sex workers and MSM.
These protocols have in the mean time been approved by the 
Research Project Review Panel of the Reproductive Health and 
Research Department (RHR) and the Research Ethics Review 
Committee of WHO. The protocols are freely available on the 
WHO website. Building on these achievements, RHR plans to 
conduct independent multicountry evaluations of existing prom-
ising tests and technologies starting from 2017, as an essential 
next step to advance the understanding of performance, feasi-
bility, acceptability and utility of existing STI POCTs, to develop 
an investment case for the implementation of STI POCTs within 
national STI control and prevention programmes and to inform 
and promote the development of appropriate STI POC diag-
nostic platforms.
High-quality evaluations in laboratory and real-world settings 
include evaluating sensitivity and specificity, and predictive 
values, and determining optimal operational characteristics of 
STI POCTs in sample sets from high-prevalence and low-prev-
alence clinical settings and in a variety of populations, for both 
screening for asymptomatic STIs and for case management.28 
The clinical utility should be comprehensively evaluated, by 
morbidity/mortality and adverse event profiles of the target 
infections.
The IEG emphasised that the required level of sensitivity 
depends on the context of the site, including among others 
access, laboratory infrastructure and quality assurance. The 
evaluations should be carried out opportunistically and take 
advantage of having a rapid turnaround time for test results 
to determine whether the POCT can be used to streamline 
patient pathways and improve the efficiency of the healthcare 
system.29 30 The ecology of the site should be comprehensively 
assessed. The paper on clinic-based evaluation of syphilis POCTs 
in Verona, included in this supplement, suggested that despite 
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low sensitivity, lower than the minimum set in the TPPs, predic-
tive values can still be acceptable for rolling out POCT testing.
Specifically for syphilis POCTs, the experts suggested that the 
results of evaluations in ANC should be used to reconsider the 
treatment algorithm. In some settings, the patients might not 
come back for the result of the reference test and consequent 
treatment. If the risk of missing to treat a syphilis case is high, 
then presumptive treatment should be considered. The IEG also 
raised the issue of including the partners of pregnant women in 
the evaluations.
The evaluations should also help to clarify what the minimal 
time should be between the POCT and the (potential) infection 
and when to retest after risk or treatment.
To accelerate the introduction of promising tests, they should 
be evaluated before they become commercially available.
Lastly, the IEG noted that conducting POCT evaluations can 
be a vehicle to assess the quality of participating laboratories and 
provide capacity building if needed.
Determine local preferences and perceptions of patients and 
providers towards STI POCTs
The IEG called for more studies to determine local preferences 
and perceptions on the use of STI POCTs in clinic-based and 
community-based outreach settings. Qualitative studies should 
assess attitudes, the perceived usefulness and changes in the 
management of STIs, which might result in more timely and 
targeted treatment, earlier commencement of partner notifica-
tion and reduced follow-up efforts. Providers should be ques-
tioned about their confidence in POCT results and consequent 
treatment decisions and changes in job satisfaction. As shown 
in figure 2, even though POCTs can shorten episodes of care, 
managing positive test results in a shorter time frame can also 
be challenging.31
proGrAmme
Gaps
The IEG pointed to the lack of evidence for the potential 
programmatic impact of STI POCTs. Programme science 
should help to address the gap between the evidence of accept-
able test performance and programme design, and assessing 
how implementation and evaluation of test deployment 
effectively answers public health needs and improves patient 
outcomes.32
Guidelines, recommendations and regulatory approval for 
POCTs are scattered, impeding systematic inclusion of POCTs 
in policies as well as building a strong investment case. The few 
cost and cost-effectiveness publications about POC testing for 
STIs are encouraging, but more work should be done on evalu-
ating the actual costs of implementing POCTs tests.33
the way forward
Accelerate the development of STI POCT guidelines and 
harmonisation of regulatory approval
If POCTs are to be effective STI diagnostics of the future in 
primary care centres in low- and middle-income countries, there 
should be a regularly updated set of easy-to-use guidelines and 
recommendations for use of POCTs for STI case management, 
screening of asymptomatic infections and surveillance.
WHO has recently published an information note on the use 
of dual HIV/syphilis rapid diagnostic tests with the main focus 
on antenatal services.34 This is an important step towards the 
integration of dual HIV/syphilis POCTs into guidelines for 
Figure 2 Potential influences on acceptability of a POCT to operators in remote health services. Reprinted from “I Do Feel Like a Scientist at Times”: 
A Qualitative Study of the Acceptability of Molecular Point-Of-Care Testing for Chlamydia and Gonorrhoea to Primary Care Professionals in a Remote 
High STI Burden, by Natoli et al.31 All PLOS content is available under CC BY (Creative Commons Attribution).
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management of syphilis in pregnant women, aiming to advance 
the dual elimination of HIV/syphilis.
The IEG suggested a review to determine the regulatory 
approval frameworks, procurement mechanisms and distributors 
in settings of interest around the world, this could be informa-
tive for both the evaluation of POCTs as for the manufacturers.
Plan for introduction in advance
The approach to introducing POCTs to healthcare systems 
should consider all its aspects in advance of product intro-
duction, including patient information, experiences, ideas 
for uptake, and the clinic and social systems in the local area. 
Crowdsourcing and using non-traditional ways to include 
populations in STI POCT provision35 might increase commu-
nity engagement, essential for successful implementation of an 
STI POCT strategy.36
Implementation studies should be conducted to determine 
staff training needs and inform the development of general and 
context-specific and population-specific trainings.
Anticipate potential tensions of STI POCT introduction by modelling 
the impact on health systems
The technological innovations of POCTs allow for a shift in 
the health system towards more decentralisation. Decentralised 
testing has tremendous advantages in accessibility of the services 
and follow-up, but places considerable pressure on health 
systems, particularly in terms of personnel, infrastructure and 
ensuring quality of service.37
Moving towards decentralisation of testing could be seen 
as a concern for future stability by laboratories, as some of 
their tasks regarding STI-testing would disappear. The EIG 
suggested assessing the capability and willingness of laborato-
ries to accept a new role: they should monitor and evaluate STI 
testing both during and after the shift to POCTs. The laboratory 
should become both a command and training centre for POCTs 
and their providers.38
Harmonisation of critical elements of new pathways to deliver 
STI POCTs, particularly over-the-counter, should be antici-
pated. Different public health programmes, for both commu-
nicable and non-communicable diseases, should collaborate to 
harmonise delivery systems for a large spectrum of existing and 
upcoming POCTs, reducing potential tensions between different 
parties involved in procurement, delivery, use and postmarket 
monitoring and evaluation.
If connectivity is adequately implemented, a big part of the 
disruptive potential of POCT introduction can be minimised. 
Health systems could improve their efficiency through connec-
tivity solutions, facilitating supply chain management to avoid 
stock-outs and wastage, and enabling ongoing monitoring of 
test results, the performance of devices and the competency 
of the operators from each POCT-site in a country.37 The IEG 
suggested to develop mentorship programmes for both policy 
makers and programme coordinators.
The IEG acknowledged that the technologies are rapidly 
changing and opportunities need to be catalysed if manufac-
turers are to produce the STI POCTs that are needed. Experts 
urged WHO to bring manufacturers and the wider clinical 
community together, to guide development, condition funding 
and negotiate the cost.
Notwithstanding the relative scarcity of available STI POCTs, 
few companies have commercialised products developed by 
scientists in academia and industry. Clinicians and industry 
have different perceptions about the limitations of current tests. 
Therefore, industry needs to be more mindful of the require-
ments of clinicians to introduce marketable tests.13
The cost-effectiveness of introducing a new POCT and the 
potential gains in public health and economic gains should be 
modelled, considering downstream sequelae. Opportunities 
for investments and potential returns from investments in STI 
POCTs should be identified. The development of an investment 
case should be prioritised as an essential step to engage relevant 
stakeholders throughout all phases of the diagnostic develop-
ment cycle. Public health authorities should be engaged to build 
support for sustainable funding of POCTs as a programmatic 
goal to strengthen their health system.30 The IEG stressed the 
importance for countries to have a generic, crosscutting STI 
POCT policy, avoiding ad hoc decisions.
In various countries, home-grown solutions are being devel-
oped, and should be encouraged, as small to medium enter-
prises can address challenges such as importation and national 
distribution.
Encourage investment in STI POCTs
The IEG expressed the urgent need to communicate the need for 
POCTs. The global health sector strategy on STIs, endorsed at 
the 2016 World Health Assembly, creates a unique opportunity 
to amplify all elements of the current roadmap through a strong 
call for innovation in STI control and prevention.1 Development 
of partnerships in the STI POCT field and identifying groups or 
organisations that can be strong champions could work towards 
the goal of advancing a clear and compelling message for the 
need for STI POCT investment.
conclusIons
The goal of improving care and treatment of patients worldwide 
is an overarching public health goal. One way to assist in the 
modernisation of care is the development and implementation 
of POCTs. These tests could change and improve provider infor-
mation, reduce the time to effective case management of those 
Key messages
Key priorities for the advancement of development and global 
uptake of point-of-care tests for STIs.
 ► Encourage target discovery.
 ► Encourage integration and miniaturisation of sample 
preparation and target detection.
 ► Promote international and multisectorial research 
cooperation.
 ► Prioritise the development of miniaturised multiplexable 
platforms.
 ► Include researchers, manufacturers and end-users in the 
translation stage.
 ► Capitalise on the advances in connectivity for 
STI-surveillance, testing uptake and quality control.
 ► Promote standardised high-quality laboratory, clinic-based 
and utility evaluations.
 ► Determine local preferences and perceptions of patients and 
providers.
 ► Accelerate the development of guidelines and harmonise 
regulatory approval.
 ► Plan for introduction in advance.
 ► Anticipate potential tensions of introduction by modelling the 
impact on health systems.
 ► Encourage investment.
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patients with symptoms and increase screening for asymptomatic 
infections. This is a long-term goal, but the opportunity to lay 
the ground work is now available.
Meeting participants at the 2014 and 2015 technical consul-
tations outlined the priorities presented here for accelerating 
and coordinating the development and introduction of POCTs 
for STIs. These priorities are an initial starting point for a 
roadmap, which will be evolving as technology and both public 
health knowledge and information progress. Although informa-
tion gaps and hurdles remain, the current state of knowledge 
provides opportunities to advance the public health goal of the 
control, treatment and prevention of STIs.
At the present time, there is quite a rich pipeline of diagnostic 
products, but some are stalled early in the development process. 
There is a need to accelerate the evaluation of new diagnostics by 
setting up a competent network of evaluation sites ahead of time, 
harmonise regulatory approval processes with development of 
models to estimate cost-effectiveness informed by better STI-data. 
This should result in accelerated policy development. Although it 
may be some time before good POCTs can be widely implemented 
in developing country settings, it is important to advocate for 
continued development and use of these essential tools as an inte-
gral part of both the WHO STI strategy and the agenda for 2030 
and have a real impact on the lives of people globally.
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